|
US6482932B1
(en)
*
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
|
US6528640B1
(en)
*
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
|
US6617438B1
(en)
*
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
|
US7125660B2
(en)
|
2000-09-13 |
2006-10-24 |
Archemix Corp. |
Nucleic acid sensor molecules and methods of using same
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
WO2003070983A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2002097114A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
|
WO2003034985A2
(en)
*
|
2001-10-22 |
2003-05-01 |
University Of Rochester |
Telomerase interference
|
|
AU2003215161A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
ATE443776T1
(de)
*
|
2002-05-17 |
2009-10-15 |
Us Gov Health & Human Serv |
Molekulare identifizierung von aspergillus- spezies
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
US7829694B2
(en)
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
US7618948B2
(en)
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
|
FR2848573B1
(fr)
*
|
2002-12-13 |
2005-04-08 |
Exonhit Therapeutics Sa |
Compositions et methodes pour la detection et le traitement de pathologies neurodegeneratives
|
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
|
US7803781B2
(en)
*
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US7846906B2
(en)
|
2003-02-28 |
2010-12-07 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
AU2005233583B2
(en)
*
|
2004-04-08 |
2011-02-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating cardiac contractility
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20090010907A1
(en)
*
|
2004-12-14 |
2009-01-08 |
National Institute Of Immunology |
Dnazymes for Inhibition of Japanese Encephalitis Virus Replication
|
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
|
JP2010500011A
(ja)
|
2006-08-08 |
2010-01-07 |
ガンサー ハートマン |
５’リン酸オリゴヌクレオチドの構造および使用
|
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
ES2651308T3
(es)
|
2009-10-16 |
2018-01-25 |
Glaxo Group Limited |
Inhibidores antisentido de HBV
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
RU2013126706A
(ru)
|
2010-11-15 |
2014-12-27 |
Рамот Ат Тель-Авив Юниверсити Лтд. |
Дипептидные аналоги для лечения состояний, ассоциированных с образованием амилоидных фибрилл
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
CN105886506A
(zh)
|
2011-04-13 |
2016-08-24 |
Isis制药公司 |
Ptp1b 表达的反义调节
|
|
SI3505528T1
(sl)
|
2011-04-21 |
2021-04-30 |
Glaxo Group Limited |
Modulacija izražanja virusa hepatitisa B (HBV)
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
US20150197503A1
(en)
*
|
2012-07-27 |
2015-07-16 |
Bial-Portela & Cª, S.A. |
Process for the synthesis of substituted urea compounds
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
GB201408623D0
(en)
*
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
DE102015113038B3
(de)
*
|
2015-07-13 |
2017-01-19 |
Simone Kann |
Oligonucleotide und deren Verwendung
|
|
WO2017048620A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
US11634716B2
(en)
|
2017-10-16 |
2023-04-25 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Genetically modified mesenchymal stem cells for use in cardiovascular prosthetics
|
|
GB201817990D0
(en)
|
2018-11-02 |
2018-12-19 |
Univ Of Essex Enterprise Limited |
Enzymatic nucleic acid molecules
|
|
AU2022219976A1
(en)
*
|
2021-02-11 |
2023-08-10 |
Ionis Phamaceuticals, Inc. |
Compounds and methods for reducing pln expression
|
|
KR20260021596A
(ko)
|
2023-04-05 |
2026-02-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Pln 발현을 감소시키는 화합물 및 방법
|
|
AU2024308906A1
(en)
*
|
2023-06-30 |
2026-02-05 |
Atrium Therapeutics, Inc. |
Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
|
|
US20260159836A1
(en)
*
|
2024-12-05 |
2026-06-11 |
Soufflé Therapeutics, Inc. |
Oligonucleotide-mediated knockdown of pln
|
